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Objectives: The search for new TB drugs has become one of the great challenges for modern medicinal chemistry.
An improvement in the outcomes of TB chemotherapy can be achieved by the development of new, shorter,
cheap, safe and effective anti-TB regimens.
Methods: Chalcones (1a-1o) were synthesized and evaluated for their antimycobacterial activity against
Mycobacterium bovis BCG using growth inhibition assays. Compound 1a was selected as a ‘hit’ compound. The
mode of action of compound 1a, was identified by mycolic acid methyl esters (MAMEs) and fatty acid methyl
esters (FAMEs) analysis using thin layer chromatography. Dose dependent experiments were conducted by over-
expressing components of FAS-II inM. bovis BCG to confirm the target. Ligand binding using intrinsic tryptophan
assay and molecular docking were used to further validate the target.
Results: MAMEs and FAMEs analysis showed dose-dependent reduction of MAMEs with the overall abundance of
FAMEs suggesting that compound 1a targets mycolic acid biosynthesis. Direct binding of 1a to InhA was ob-
served using an intrinsic tryptophan fluorescence binding assay, and a 2-fold IC50 shift was observed with an
InhA overexpressing strain confirming InhA as the cellular target.
Conclusion: The chalcone 1a exhibits potent antimycobacterial activity, displays a good safety profile and is a
direct inhibitor of InhA, a key component in mycolic acid synthesis, validating this series for further anti-TB drug
development.
1. Introduction
Antibiotic resistance is a major global healthcare crisis. It is ex-
pected that antimicrobial resistance will overtake cancer as the leading
cause of death by 2050 (de Kraker et al., 2016). Tuberculosis (TB) is the
most devastating infectious disease caused by Mycobacterium tubercu-
losis (MTB), claiming 1.4 million lives in 2015. It has existed for mil-
lennia and remains a global health problem (Falzon et al., 2017). The
effective treatment for drug-susceptible TB is a 6-month dose regimen
of four first-line drugs: isoniazid (INH), rifampicin (RIF), ethambutol
(ETH) and pyrazinamide (PYZ). The most challenging problem with the
current TB regimen is patient compliance attributed to the length,
complexity and adverse effects commonly observed with frontline
treatment. This is further complicated by the emergence of drug re-
sistant strains. The emergence of drug-resistant TB is one of the most
dangerous threats to global TB control (Brouqui et al., 2017). The
treatment for RIF resistant TB (RR-TB), multidrug-resistant TB (MDR-
TB), and extensively drug-resistant TB (XDR-TB) takes 18–24 months,
requiring more expensive and toxic drugs (Upadhyaya et al., 2012).
There is an urgent need to develop new drugs that can shorten the
treatment regimen, that are able to treat MDR-TB and have less adverse
effects. Phenotypic screening is emerging as an important tool in the
discovery of new drugs against MTB as it allows a direct and measur-
able response of whole cells against a library of compounds measuring
and evaluating their efficacy in bacterial killing (Kotz, 2012). Advances
in high throughput screening, genome sequencing and data handling
tools have further expanded its applications allowing the discovery of
new anti-microbial compounds and new targets (Ferraris et al., 2018).
The success of whole cell phenotypic screening is evidenced by the
recent development of some new TB drugs such as bedaquiline
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(Matteelli et al., 2010) and others which are currently under study
(Singh and Mizrahi, 2017). Whereas target-based approaches have en-
countered very limited success in the antibacterial field (Abrahams
et al., 2012; Payne et al., 2007).
INH is a frontline anti-TB drug that inhibits the mycobacterial
enoyl-reductase InhA and its activity is dependent on KatG activation,
the catalase peroxidase involved in the activation of isoniazid. InhA is
an essential enzyme for the biosynthesis of a major component of the
mycobacterial cell wall, mycolic acid, through fatty acid synthesis (FAS-
II) system (Duan et al., 2014). InhA is also a target for second line drug
ethionamide (Banerjee et al., 1994). Unfortunately, between 40 and
95% of INH-resistant MTB clinical isolates have mutations in KatG gene
leading to decreased activation of INH (Hazbon et al., 2006; Seifert
et al., 2015) and therefore this pro-drug activation step of INH me-
chanism of action significantly contributes to multidrug and extensively
drug resistance in MTB isolates (Ramaswamy et al., 2003). It is there-
fore important to develop drugs that can directly inhibit InhA without
requiring activation by KatG.
Chalcones are essential intermediate compounds for the synthesis of
various heterocyclic compounds such as flavonoids and isoflavanoids
which are abundant in edible plants (Rachmale and Patil, 2012). Many
studies have shown that natural and synthetic chalcones display a wide
spectrum of biological activities (Chavan et al., 2015) including anti-TB
activity (Gomes et al., 2017).
In view of their therapeutic potential, a series of 15 synthetic
chalcones were evaluated in vitro for their anti-mycobacterial activity
against the MTB model organism M. bovis BCG using whole cell phe-
notypic screening. In addition, the mode of action of the hit compound
was elucidated and validated using biochemical, molecular genetics
and molecular docking approaches.
2. Materials and methods
2.1. Synthesis
Chalcones (1a-1o) were synthesized by reacting 3,4-dimethox-
ybenzaldehyde with various acetophenones by the Claisen-Schmidt
condensation (Fig. 1). The synthesized products were recrystallized
from appropriate solvents and were characterized by spectral analysis,
melting point, infrared spectroscopy, 1H and 13C NMR and mass spec-
trometry.
2.2. Anti-mycobacterial evaluation
Minimum inhibitory concentrations (MICs) were determined for
these synthesized compounds by broth micro-dilution according to CLSI
recommended procedure as described previously (Abrahams et al.,
2012). To prepare stocks, M. bovis BCG Pasteur was grown to mid-
logarithmic phase (Optical density 600 nm = 0.5–0.8) in Middlebrook
7H9 broth (Difco) supplemented with 10% albumin dextrose catalase
supplement (ADC); 0.25% (v/v) glycerol and 0.05% (v/v) Tween 80.
MIC of each test compound was determined against M. bovis BCG in
a 96-well flat-bottom, microtitre plate in a final volume of 200 µl. Series
of two-fold dilutions of test compounds starting from 200 µg.ml−1 and
the standard (RIF) were prepared in Middlebrook 7H9 medium from
stock solution (10 mg.ml−1 in DMSO). The inoculum was standardized
to approximately 1 × 106 cfu.ml−1 and 100 µl was added to each well.
All plates were sealed using seals (Sigma, UK Z380069) to prevent
desiccation of the peripheral wells and incubated at 37 °C without
shaking for six days. A 25 µl resazurin solution (0.02% w/v in sterile
distilled water) was added to each well and the plates were incubated
for 24 h. The MIC was defined as the lowest concentration where there
was no colour change of resazurin (blue) to resarufin (pink).
Experiments were performed with biological replicates (n = 3).
2.3. MTT assay for cytotoxicity
The in vitro cytotoxicity of all synthesized chalcones (1a-1o) was
assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay against J774 cells at a concentration range of
200–0.5 μg.ml−1. Exponentially growing mouse macrophages (J774) in
Dulbecco’s Modified Eagle’s medium (DMEM) (supplemented with 10%
FBS and 1% penicillin and streptomycin) were seeded at a density of
50,000 cells.ml−1 into a 96-well plate and incubated overnight at 37 °C
(Ling et al., 2015). The medium was replaced with fresh medium
containing synthesized chalcones (1a-1o) and after 24 h of incubation
at 37 °C, MTT was added to the cells. After 2 h, the formed crystals were
dissolved in isopropanol and the absorbance was recorded using plate
reader at A540nm. The experiments were performed in biological re-
plicates of n = 3.
2.4. Scanning electron microscopy (SEM)
All chemicals and reagents for electron microscopy were obtained
from Sigma Aldrich, M. bovis BCG (Pasteur strain, ATCC 35734) cul-
tures were grown to early log phase (optical density at 600 nm, 0.2), at
which time cells were treated with 1a (60 µg.ml−1), followed by in-
cubation at 37 °C for five days. Cells were harvested by low-speed
centrifugation and washed in 0.1 M cacodylate (CACO) buffer (pH 7.3).
Washed cells were then fixed on glass coverslips in 0.1 M CACO buffer
(pH 7.3) containing 2.0% glutaraldehyde–osmium tetroxide (1:1, v/v)
for 45 min at 4 °C (Parrish et al., 2001). Secondary fixation was done at
4 °C overnight in a mixture of 4.0% formaldehyde and 1.0% glutar-
aldehyde. Samples were post-fixed at room temperature for 1 h in 0.1 M
CACO buffer containing 1% tannic acid and dehydrated through a
graded ethanol series of 50, 70, 95 (twice), and 100% (three times)
(Stadtländer, 2008). The samples were air dried and coated with gold
and visualized using JEOL CarryScope JCM-5700 scanning electron
microscope.
2.5. Extraction and analysis of MAMEs and FAMEs
The inhibition of mycolic acid biosynthesis by 1a was investigated.
The qualitative and quantitative biochemical characterization of the
mycolic acid pattern by thin layer chromatography (TLC) can be used to
address how drugs alter mycolic acid biosynthesis (Alahari et al.,
2007a,b; Hartkoorn et al., 2012). To assess the effect of 1a on both
mycolic acid and fatty acid synthesis in M. bovis BCG, mycolic acid
methyl esters (MAMEs) and fatty acid methyl esters (FAMEs) were
prepared from cultures following labelling with [4]-acetate (Cox et al.,
2016). Following the treatment with 1a the total FAMEs and α-myco-
late and keto-mycolic acid methyl esters (α- and k-MAMEs) were ex-
tracted and analyzed by autoradiography TLC using petroleum ether-
diethyl ether (95:5) six times as described in Parish and Stoker (Parish
and Stoker, 1998).
Fig. 1. Chalcone synthesis reaction scheme (1a-
1o).
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2.6. MIC shift assay
The mycobacterial expression vector pMV261 was cloned with M.
tuberculosis FAS-II enzymes KasA, KasB, FabH, HadABC, MabA, MabB
and InhA. Each respective plasmid was electroporated intoM. bovis BCG
and the MIC assay was performed using these transformed strains,
along with an empty pMV261 control strain (Larsen et al., 2002). The
data points were collected in triplicate and an IC50 (50% inhibition of
growth) values for each strain were obtained using GraphPad Prism
software. The experiments were performed in biological replicates of
n = 3.
2.7. Intrinsic tryptophan fluorescence ligand binding assay
Using intrinsic tryptophan fluorescence, a ligand binding assay was
performed to measure the binding affinity of 1a to InhA enzyme.
Briefly, InhA (10 µM) was incubated for 5 min in a buffer solution
(25 mM HEPES, 10% glycerol and 300 mM NaCl, pH 8) at 25 °C fol-
lowed by addition of increasing concentrations 0.3–70 μM of either
triclosan (positive control) or compound 1a. DMSO concentration was
maintained at less than 1% in the assay. The measurements were ob-
tained as a change in tryptophan fluorescence by Hitachi F7000 spec-
trophotometer at an excitation wavelength of 350 nm and emission
wavelength at 470 nm. Data were recorded using Hitachi FL Solutions
4.6 software. The experiments were performed in biological replicates
of n = 3.
2.8. Molecular docking
2.8.1. Protein preparation
The X-ray crystal structure of InhA complexed with PT506 inhibitor
(5UGU) was obtained from protein data bank (www.rcsb.org). Protein
preparation wizard module of Schrödinger suite was used to prepare
the protein by adding hydrogens, fixing error like missing side chains,
assigning correct bond orders, adjusting the ionization and tautomeric
states (via epik). All the water molecules have been deleted.
Optimisation of the hydrogen bonding network and the orientation of
the hydroxyl/thiol groups, terminal amide groups in Asn, Gln and His
states was carried out using the ProtAssign algorithm. Finally, re-
strained minimization was carried out on all the atoms using OPLS3
force fields, with converge heavy atoms to RMSD set to 0.3 Å (default).
2.8.2. Ligand preparation
Compound 1a was drawn and prepared using Ligprep module,
which performed addition of hydrogens, 2D to 3D conversion, gen-
eration of ionization and tautomeric states (via Epik) at physiological
pH 7.0 ± 2.0, and also generated ring conformations using default
settings. Compound 1a was energy minimized using OPLS3 force fields.
2.8.3. Docking studies
The X-ray crystal structure of InhA (PDB ID 5UGU, resolution
1.95 Å) was used for structure-based docking of compound 1a. The
Receptor Grid generation was carried out by identifying the PT506
inhibitor in the 5UGU crystal structure and excluding it from the grid
generation. The triazole based inhibitor PT506 present in 5UGU crystal
structure was redocked to verify our Glide docking protocol. Glide
docking successfully reproduced the crystallographic binding mode of
triazole based inhibitor with a high docking score of −11.00. The
RMSD value between the heavy atoms of the Glide predicted pose and
the crystallographic binding pose is 0.31 Å, indicating close agreement.
We have used this docking protocol to dock compound 1a to 5UGU
(InhA) using Schrödinger GLIDE, in standard precision (SP) mode.
Molecular modelling studies were performed primarily using
Schrödinger drug design software suite (Schrödinger, 2017).
3. Results
The MIC values (μg.ml−1) of chalcones (1a-1o) (Table 1) were ob-
tained with RIF as the standard. The results were obtained in duplicate
by testing in concentrations ranging 200–0.3 μg.ml−1. Compounds that
exhibited higher selectivity index (SI) values for J774 cells were con-
sidered nontoxic. Hence compound 1a (SI = 8.4) was selected for mode
of action (MoA) elucidation.
Preliminary SEM examination of the 1a-treated cells indicate defi-
nite morphological changes occurred in comparison to the control due
to the action of the drug. The SEM examination revealed in general
there are some degraded cells in 1a-treated cells. The main features of
the cells in control specimen (Fig. 2a-c) are smooth surface and char-
acteristic rod like shape. Whereas the cells exposed to 1a for five days
showed elongation, wrinkles and bulging (Fig. 2d-f).
3.1. Mode of action
3.1.1. FAMEs and MAMEs analysis
To identify the biological target of 1a, inhibition of mycolic acid
Table 1
Shows chalcone compounds 1a to 1o with various substituents at R1, R2 and R3 positions with their molecular weights and predicted Clogp values. The MIC of each
compound is shown in µg.ml−1 against M.bovis BCG with the IC50 values and the selective index (SI) for J774 cell line. Lipophilicities calculated by ChemDraw
Professional 15.0, part of ChemOffice (Perkin Elmer, UK).
Compound Substituents Mol.wt
(g.mol−1)
Clogp MIC (µg.ml−1) J-774 (IC50)
(µg.ml−1)
SI = IC50/MIC
R1 R2 R3 M.bovis BCG
1a H H H 270.33 3.35 6.25 50 8.0
1b H Br H 349.22 4.18 – 25 –
1c Br H H 349.22 4.18 25 25 1
1d H H Br 349.22 4.18 12.5 25 2.0
1e H Cl H 304.77 3.91 – 12.5 –
1f Cl H H 304.77 3.91 12.5 12.5 1
1g H H Cl 304.77 3.91 200 12.5 0.06
1h H H F 288.32 3.51 25 100 4
1i H H OCH3 300.35 3.23 50 100 2
1j H H CH3 284.35 3.84 25 25 1
1k H H C6H5 346.43 5.03 100 25 0.25
1l H NO2 H 315.32 3.48 100 25 0.25
1m CH3 H H 284.35 3.84 50 25 0.5
1n H H NO2 315.32 3.48 200 50 0.25
1o Cl H Cl 339.21 4.47 200 6.25 0.03
RIF – – – 0.1
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biosynthesis was investigated. As shown in Fig. 3 there was a dose-
dependent decrease in the production of α- and k-MAMEs upon treat-
ment with 1a. There is also an accumulation of FAMEs in a dose-de-
pendent manner. This accumulation of FAMEs and reduction of MAMEs
suggests that test compound 1a inhibits mycolic acid biosynthesis (FAS-
II inhibition) in mycobacteria which causes cessation of the essential
mycolic acids. This inhibition of FAS-II is desirable as the inhibition of
FAS-I is not specific since mammalian fatty acid synthases are similar to
FAS-I. Original auto-radiograph of MAMEs and FAMEs is included in
supplementary data (Fig. S-1).
3.1.2. MIC shift
To further corroborate that 1a inhibits mycolic acid biosynthesis,
MIC shift assay was performed. M. bovis BCG containing the
pMV261::inhA plasmid exhibited an increased IC50 over the empty
vector control (16 μg.ml−1 compared to 8 μg.ml−1 respectively). The
results suggest that the ample growth of InhA over-expressor strain was
observed as shown by increase in absorbance (Fig. 4), indicating an
increase in resistance. This further validates InhA as the target of the
chalcone compound series. The data for the other overexpressing
components of FAS-II are listed in supplementary data (Fig. S-2).
3.1.3. Intrinsic tryptophan fluorescence InhA binding assay
Intrinsic tryptophan fluorescence was used to investigate InhA as
the target enzyme for 1a. Ligand binding assays using InhA were con-
ducted to establish the equilibrium dissociation constant (Kd) values for
compounds 1a and triclosan. Binding affinity is the strength of the
binding interaction between a protein and its ligand, that is measured
and reported by Kd values. Triclosan is well known for its direct binding
affinity towards InhA. The experimental results suggest that both
Triclosan and 1a bind with similar affinity to InhA, as reflected by the
Kd values of 10.29 µM and 11.65 µM respectively providing the ne-
cessary evidence for target validation (Fig. 5). Kd values (mean ± s.d)
resulting from non-linear least-squares fitting of a one-site specific
binding model are listed in supplementary Table S-1.
a b c
d e f
Fig. 2. Scanning electron micrographs of untreated and 10 X MIC (60 µg/ml) 1a treated Mycobacterium bovis BCG cells for 5 days. (a-c) untreated M. bovis BCG cells;
(d-f) 60 µg/ml 1a treated M. bovis BCG cells analyzed using JEOL CarryScope JCM-5700 scanning electron microscope. There was significant proportion (76%) of
cells showing morphological changes such as bulging, elongation and wrinkling of cell surface.
Fig. 3. Inhibition of mycolic acid biosynthesis by Chalcone 1a. Mycobacterium
bovis BCG cultures, labelled with [14C]-acetate were exposed to increasing
concentrations of 1a. The α- and k-MAMEs and FAMEs were extracted and
analysed by autoradiography-TLC. From left to right: Untreated, treated with
3 μg.ml−1 of 1a, treated with 6 μg.ml−1 of 1a, treated with 12 μg.ml−1 of 1a
and treated with 18 μg.ml−1 of 1a..
Fig. 4. Investigation of the impact of InhA overexpression on sensitivity to
compound 1a. Absorbance values were read at 0 days and after 7 days for EV
and InhA strain. Using Mycobacterium bovis BCG containing a constitutive
plasmid (pMV261) expressing InhA, IC50 was compared to an empty vector
control. The overexpressing strain demonstrated an increase in IC50 value
16 μg.ml−1 compared to 8 μg.ml−1 for the empty vector strain. The experi-
ments were performed in biological replicates of n = 3 and the error bars re-
present the standard error bars of mean (SEM).
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3.1.4. Binding mode analysis of compound 1a
Predicted binding mode of the compound 1a with the binding site of
InhA (Fig. 6a and b) suggested that it occupies the hydrophobic cavity
of the substrate binding site. Substrate binding pocket is composed of
hydrophobic groups from the side chains of Tyr 158, Phe 149, Met 199,
Met 166 and Pro 193. Compound 1a (SP docking score −9.14) is in-
volved in good hydrophobic interactions with these amino acids and
also involved in van der Waals interactions with the surrounding amino
acids Pro193, Met 199, Phe 149. In addition, the phenyl ring of com-
pound 1a undergoes Pi-Pi stacking interactions with the phenyl ring of
Phe 149. It appears that hydrophobic, van der Waals, Pi-Pi stacking
interactions play a dominant role in the binding affinity of the com-
pound 1a.
4. Discussion:
Treatment of drug resistant strains of M. tuberculosis has become a
global problem and WHO has declared the priority of new drugs to
overcome antibiotic resistance. To overcome this problem many ap-
proaches including the re-purposing of broad spectrum anti-bacterials,
target-based programs on antimycobacterial enzymes and phenotypic
screening have been widely reported (Chetty et al., 2017). The target to
drug approach for drug discovery is time consuming and costly. In
comparison, a drug to target approach that involves phenotypic
screening utilizes whole cells and is much quicker and establish potent
inhibitors at low cost. In this study we have synthesized 15 chalcones,
fully characterized them and using whole cell phenotypic screening
approach showed that most of these chalcones showed anti-
mycobacterial activity (Table 1) with MIC in the range
6.25–200 µg.ml−1 against M. bovis BCG. Compound 1a was the most
potent againstM. bovis BCG with MIC of 6.25 µg.ml−1 and showed SI of
8.0. Of the fifteen compounds synthesized 1a, where R substituents are
all hydrogens, showed the best activity. The compounds that had sub-
stituents other than hydrogen did not display the same level of activity.
This may reflect poor binding of the substituents in the other fourteen
compounds. The compounds which also showed significant activity
were those which contained a chlorine or a bromine atom. Previously
reported work on in vitro testing on antifungal and antimycobacterial
activity of a series of pyrazine analogues of chalcones showed the
highest potency was exhibited by derivatives with a chlorine or a
bromine atom in positions 2 and 4 of the benzoyl ring (Kucerova-
Chlupacova et al., 2016). The ortho chloro-substituent (R1 = Cl),
compound 1f, showed the next best activity compared to compound 1a.
When the chlorine atom is positioned in the para position (R3 = Cl),
compound 1g, there is quite a substantial drop in activity, but when the
R3 position is occupied by a bromine atom, compound 1d, the activity is
comparable to compound 1f. This may indicate that electronic factors
do not play an important role in activity. Calculated lipophilicities of all
tested compounds are provided in table 1. They do not correlate with
the biological activity of the compounds. The activity of compounds 1a-
1o does not show a correlation with electronic factors nor
Fig. 5. Saturation binding assay using intrinsic tryptophan fluorescence to
quantify association of increasing concentrations of ligands 1a and triclosan
with InhA (n = 3). The figure shows the Kd values (11.65 µM and 10.29 µM) for
triclosan and 1a. Data were fitted using GraphPad Prism, relative fluorescence
units (RFU). The experiments were performed in biological replicates of n = 3
and the error bars represent the standard error bars of mean (SEM).
a b
Fig. 6. (a) Shows the predicted interaction mode of compound 1a within the binding site of the InhA of Mycobacterium tuberculosis. InhA is shown as secondary
structures with helices (green) and sheets (yellow). Compound 1a is shown in the teal capped stick format. Van der Waals surface around compound 1a is shown in
mesh format. NAD is shown in element type format (Nitrogen in blue, Oxygen in red, Phosphorous in magenta). Pi-Pi stacking interaction is shown as teal dashed line
between the phenyl rings of Phe 149 and the compound 1a. This image has been generated by using Schrodinger drug design software. (b) Shows the ligand
interaction map of the compound 1a with the active site residues of the InhA. The proposed interaction mode of compound 1a is shown in the stick format. Pi-Pi
stacking is shown in green line.
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lipophilicities; it is therefore surmised that the conformation of parti-
cular molecules, influenced by the position of the halogen atom, may
play an important role. Our results are in accordance with previous
studies where it has been shown that chalcone derivatives show activity
against gram-negative, gram-positive bacteria and mycobacteria (Gond
et al., 2013; Lin et al., 2002; Sivakumar et al., 2007; Yadav et al., 2014).
A series of 5-nitro-substituted heteroaryl chalcones were synthesised
using QSAR driven approach (Gomes et al., 2017). They have shown
low MICs against non-replicating M. tuberculosis H37Rv and RIF and
INH mono-resistant strains. As the functional groups attached to the 3
carbon α,β unsaturated carbonyl structure are different from our
chalcone series the results cannot be directly compared to each other.
However, having a 5-nitro-heteroaryl group instead of an aromatic
carbon ring B of our chalcone series seems advantageous resulting
lower MICs values.
In the present study using in vitro biochemical and modelling ex-
periments, we have shown that our hit compound 1a specifically targets
mycolic acid synthesis component InhA. The mycolic acids are the es-
sential characteristic components of mycobacterial cell wall and in-
volves two distinct fatty acid synthesis pathways- FAS-I and FAS-II. The
FAS-II system enables fatty acid elongation forming meromycolic acids
in the presence of condensing enzymes KasA and KasB (Kremer et al.,
2002), a keto reductase MabA (Marrakchi et al., 2002), a dehydratase
HadABC (Sacco et al., 2007), and an enoyl acyl carrier protein re-
ductase InhA (Banerjee et al., 1994). The lipid analysis in our study
showed dose dependent accumulation of FAMEs with depletion of
MAMEs confirming that compound 1a specifically inhibits FAS-II in
mycolic acid biosynthesis (Fig. 3). Furthermore, the mycobacterial
strains transformed with overexpression plasmids (pMV261) containing
InhA conferred an increase in resistance to compound 1a and no re-
sistance was observed with empty vector pMV261 (Fig. 4). This further
validates that mycolic acid synthesis is inhibited by compound 1a and
InhA is the possible target. InhA is one of the best validated targets in
the treatment of TB. The pro drug INH is oxidatively activated by the
catalase-peroxidase KatG and covalently binds to NAD to form an ad-
duct that inhibits the activity of InhA (Rawat et al., 2003). It is an-
ticipated that a drug directly targeting InhA in a different location than
activated INH and not requiring activation by KatG may have bacter-
icidal and sterilizing properties superior to those of INH.
To ascertain whether compound 1a directly targets InhA without
requiring KatG activation, we conducted ligand binding tryptophan
flourescence assay. Triclosan inhibits InhA directly, without requiring
the activation of KatG (Gurvitz, 2010). It was observed that compound
1a shows similar binding affinity to triclosan (Fig. 5), thus suggesting
that compound 1a directly inhibits InhA. Computational studies also
provided further evidence of the binding affinity of compound 1a to-
wards the target site InhA as shown in Fig. 6(a and b). Compound 1a
showed hydrophobic interactions with Tyr 158, Phe 149, Met 199, Met
166 and Pro 193 and is also involved in π-π interactions with Phe 149
residues of InhA. It is also involved in van der Waals interactions with
surrounding amino acids. Similar to our work Yadav and co-workers by
their docking studies have shown that the chalcone derivatives bind to
InhA with good affinity as compared with the standard inhibitors such
as triclosan and isoniazid (Yadav et al., 2014). They also showed hy-
drophobic interactions with Tyr and Phe residues but in addition to
these residues they also showed the interaction with other amino acid
residues of the InhA, including aliphatic (Gly-93 and Ile-200), sulfur
containing (Met-159 and Met-206), cyclic (Pro-191), and basic (Lys-
163) residues. Recently Joshi et al. (2017) have used target to drug
approach and shown that compounds such as pyrrolyl benzohydrazide
derivatives inhibit InhA directly. Similarly Stular et al. (2016) using
molecular docking found three novel compounds that bind InhA. Bio-
logical testing confirmed that these compounds inhibit InhA. Muradás
et al. (2018) have studied the inhibitory activity of quinoxaline derived
chalcones against M. tuberculosis and showed MIC values in the range of
3.13–12.5 µg.ml−1 which are very similar to our results. However, in
contrast to our results they showed that these chalcones did not inhibit
mycolic acid synthesis as they showed low MICs against M. tuberculosis
strains that have mutations in the katG or inhA genes. The results cannot
be directly compared due to the difference in the functional groups.
5. Conclusion
Following the identification and validation of the molecular target,
target-specific optimization of compound 1a will be pursued to improve
efficacy and reduce toxicity. This will be achieved using computational
and synthetic chemistry techniques to rationally design novel inhibitors
based on our understanding of ligand–protein (1a-InhA) interaction.
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